Quest Diagnostics Lifts Guidance on Organic Growth

Dow Jones

Oct 21

By Dean Seal

Quest Diagnostics raised its profit and revenue outlook for the year after strong organic growth and acquisitions boosted its top and bottom lines in the third quarter.

The provider of diagnostic information services said Tuesday that organic revenue growth in the latest completed quarter hit 6.8%, while acquisitions boosted the top line higher.

Quest is now guiding for $10.96 billion to $11 billion in revenue for 2025, up from a prior outlook for $10.8 billion to $10.92 billion, and adjusted earnings of $9.76 to $9.84 a share, up from $9.63 to $9.83 a share.

Shares advanced 2.4% to $195 in premarket trading.

For the third quarter, the Secaucus, N.J., company posted a profit of $245 million, or $2.16 a share, compared with $226 million, or $1.99 a share, in the same quarter a year earlier.

Stripping out one-time items, adjusted earnings were $2.60 a share, topping analyst forecasts by a dime, according to FactSet.

Revenue jumped 13% to $2.82 billion, ahead of analyst estimates for $2.74 billion.

During the quarter, Quest completed the acquisition of select dialysis testing assets from Fresenius Medical Care and separately began to scale clinical lab testing for Fresenius Medical Care's U.S. dialysis customers.

Write to Dean Seal at dean.seal@wsj.com

(END) Dow Jones Newswires

October 21, 2025 07:12 ET (11:12 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2577182458"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2577182458\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2577182458?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-21 19:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2577182458","market":"hk","top_or_hot":-1,"title":"Quest Diagnostics Lifts Guidance on Organic Growth","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Dean Seal \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Quest Diagnostics raised its profit and revenue outlook for the year after strong organic growth and acquisitions boosted its top and bottom lines in the third quarter. \n</p>\n<p>\n  The provider of diagnostic information services said Tuesday that organic revenue growth in the latest completed quarter hit 6.8%, while acquisitions boosted the top line higher. \n</p>\n<p>\n  Quest is now guiding for $10.96 billion to $11 billion in revenue for 2025, up from a prior outlook for $10.8 billion to $10.92 billion, and adjusted earnings of $9.76 to $9.84 a share, up from $9.63 to $9.83 a share. \n</p>\n<p>\n  Shares advanced 2.4% to $195 in premarket trading. \n</p>\n<p>\n  For the third quarter, the Secaucus, N.J., company posted a profit of $245 million, or $2.16 a share, compared with $226 million, or $1.99 a share, in the same quarter a year earlier. \n</p>\n<p>\n  Stripping out one-time items, adjusted earnings were $2.60 a share, topping analyst forecasts by a dime, according to FactSet. \n</p>\n<p>\n  Revenue jumped 13% to $2.82 billion, ahead of analyst estimates for $2.74 billion. \n</p>\n<p>\n  During the quarter, Quest completed the acquisition of select dialysis testing assets from Fresenius Medical Care and separately began to scale clinical lab testing for Fresenius Medical Care's U.S. dialysis customers. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Dean Seal at dean.seal@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 21, 2025 07:12 ET (11:12 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Quest Diagnostics Lifts Guidance on Organic Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nQuest Diagnostics Lifts Guidance on Organic Growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-10-21 19:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Dean Seal \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Quest Diagnostics raised its profit and revenue outlook for the year after strong organic growth and acquisitions boosted its top and bottom lines in the third quarter. \n</p>\n<p>\n  The provider of diagnostic information services said Tuesday that organic revenue growth in the latest completed quarter hit 6.8%, while acquisitions boosted the top line higher. \n</p>\n<p>\n  Quest is now guiding for $10.96 billion to $11 billion in revenue for 2025, up from a prior outlook for $10.8 billion to $10.92 billion, and adjusted earnings of $9.76 to $9.84 a share, up from $9.63 to $9.83 a share. \n</p>\n<p>\n  Shares advanced 2.4% to $195 in premarket trading. \n</p>\n<p>\n  For the third quarter, the Secaucus, N.J., company posted a profit of $245 million, or $2.16 a share, compared with $226 million, or $1.99 a share, in the same quarter a year earlier. \n</p>\n<p>\n  Stripping out one-time items, adjusted earnings were $2.60 a share, topping analyst forecasts by a dime, according to FactSet. \n</p>\n<p>\n  Revenue jumped 13% to $2.82 billion, ahead of analyst estimates for $2.74 billion. \n</p>\n<p>\n  During the quarter, Quest completed the acquisition of select dialysis testing assets from Fresenius Medical Care and separately began to scale clinical lab testing for Fresenius Medical Care's U.S. dialysis customers. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Dean Seal at dean.seal@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 21, 2025 07:12 ET (11:12 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1854103824.USD","symbol_name":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) INC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2577182458","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2577182458","pubTimestamp":1761045120,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Quest Diagnostics raised its profit and revenue outlook for the year after strong organic growth and acquisitions boosted its top and bottom lines in the third quarter.The provider of diagnostic information services said Tuesday that organic revenue growth in the latest completed quarter hit 6.8%, while acquisitions boosted the top line higher.Quest is now guiding for $10.96 billion to $11 billion in revenue for 2025, up from a prior outlook for $10.8 billion to $10.92 billion, and adjusted earnings of $9.76 to $9.84 a share, up from $9.63 to $9.83 a share.Shares advanced 2.4% to $195 in premarket trading.For the third quarter, the Secaucus, N.J., company posted a profit of $245 million, or $2.16 a share, compared with $226 million, or $1.99 a share, in the same quarter a year earlier.Stripping out one-time items, adjusted earnings were $2.60 a share, topping analyst forecasts by a dime, according to FactSet.Revenue jumped 13% to $2.82 billion, ahead of analyst estimates for $2.74 bill","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1854103824.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) INC","BK4196":"保健护理服务","BK4588":"碎股","LU1854104046.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) ACC","BK4583":"猴痘概念","BK4585":"ETF&股票定投概念","BK4567":"ESG概念","DGX":"奎斯特诊疗"},"translate_title":"Quest Diagnostics提高有机增长指导","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DGX":1.5},"content_text":"By Dean Seal \n\n\n \n\n\n  Quest Diagnostics raised its profit and revenue outlook for the year after strong organic growth and acquisitions boosted its top and bottom lines in the third quarter. \n\n\n  The provider of diagnostic information services said Tuesday that organic revenue growth in the latest completed quarter hit 6.8%, while acquisitions boosted the top line higher. \n\n\n  Quest is now guiding for $10.96 billion to $11 billion in revenue for 2025, up from a prior outlook for $10.8 billion to $10.92 billion, and adjusted earnings of $9.76 to $9.84 a share, up from $9.63 to $9.83 a share. \n\n\n  Shares advanced 2.4% to $195 in premarket trading. \n\n\n  For the third quarter, the Secaucus, N.J., company posted a profit of $245 million, or $2.16 a share, compared with $226 million, or $1.99 a share, in the same quarter a year earlier. \n\n\n  Stripping out one-time items, adjusted earnings were $2.60 a share, topping analyst forecasts by a dime, according to FactSet. \n\n\n  Revenue jumped 13% to $2.82 billion, ahead of analyst estimates for $2.74 billion. \n\n\n  During the quarter, Quest completed the acquisition of select dialysis testing assets from Fresenius Medical Care and separately began to scale clinical lab testing for Fresenius Medical Care's U.S. dialysis customers. \n\n\n \n\n\n  Write to Dean Seal at dean.seal@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 21, 2025 07:12 ET (11:12 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}